米国のバイオテクノロジー市場分析

Abstract

RNCOS report “US Biotech Market Analysis” provides an updated and detailed overview of the U.S Biotechnology industry. It examines the emerging trends and provides exclusive forecasts, segment wise snapshots of biotechnology industry in U.S.

Key Findings

• Growing at the rate of 13.95% from the year 2005, U.S Biotechnology industry is expected to touch the mark of US$ 131.8 Billion by the end of 2010.
• Biotechnology will play an important role in Agricultural sector by developing large number of genetically modified seeds.
• The biomedical sector accounts for the major share of overall biotech industry in US and will continue to dominate in future as well.
• The clinical trial industry will cross US$ 30 Billion mark by 2011.

Key Issues and Facts Analyzed

The research report also addresses the issues and facts that are critical to your success:

• Major market trends in the US Biotechnology industry?
• Where will the market be after 5 years?
• What opportunities exist in US Biotechnology industry?
• What are the driving factors for the US Biotechnology industry?
• Challenges faced by Biotechnology industry?
• Who are the main players in the US Biotechnology industry?

Key Players Analyzed

This section provides the overview, key facts financial information of prominent players in the Indian Biotechnology Industry like Chiron Corporation, Amgen Inc., Biogen Idec Inc., Applied Biosystems, Genentech, and Baxter International Inc.

Research Methodology Used

Information Sources

Information has been sourced from namely, books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to access to more than 3000 paid databases.

Analysis Methods

The analysis methods include the following: Ratio Analysis, Historical Trend Analysis, Linear Regression Analysis using software tools, Judgmental Forecasting and Cause and Effect Analysis.

Table of Contents

1. Analyst View

2. Research Overview

3. Industry Overview

• 3.1 Biotechnology Industry Worldwide
• 3.2 US Biotech Industry

4. Industry Performance

• 4.1 Bio Medical
  • 4.1.1 Current Biomedical Business Models
    • 4.1.1.1 Fully Integrated Companies (FICOs: FIPCOs, FIBCOs, FICOPs)
    • 4.1.1.2 Non Research Development Only (NRDOs)
    • 4.1.1.3 Platform Model
    • 4.1.1.4 Mixed Models
    • 4.1.1.5 Medical Device Model
  • 4.1.2 Stages of Growing Biomedical Firm
• 4.2 Agriculture Biotechnology
  • 4.2.1 Production and Economic Impacts
  • 4.2.2 Adoption of Biotechnology Derived Crops
  • 4.2.3 Biotechnology and Biofuels
• 4.3 Clinical Trials
• 4.4 Mergers and Acquisitions
• 4.5 Strategic Alliances
• 4.6 Biotech Funding (Public, Private & Venture Capital)
• 4.7 Biotech Research Parks
  • 4.7.1 Cummings Research Park, Huntsville
  • 4.7.2 ASU (Arizona State University) Research Park
  • 4.7.3 Texas Research Park
  • 4.7.4 Delaware Technology Park
  • 4.7.5 Massachusetts Biotechnology Research Park
  • 4.7.6 UK (University of Kentucky) Coldstream Research Campus
  • 4.7.7 InterTech Science Park
  • 4.7.8 Chicago Technology Park

5. US Bio Cluster

• 5.1 New York
• 5.2 North-West Pennsylvania
• 5.3 Massachusetts
• 5.4 California
• 5.5 Washington

6. Industry Analysis

• 6.1 Key Drivers
  • 6.1.1 Increasing Financing Option
  • 6.1.2 Strong and Stable Biotech Sector
  • 6.1.3 Environmental Drivers
  • 6.1.4 Sociological Drivers
  • 6.1.5 Patent System
  • 6.1.6 Federal Funding
  • 6.1.7 FDA Biopharmaceuticals Approvals
  • 6.1.8 Technology
• 6.2 Opportunities
  • 6.2.1 Opportunity for Developers of Innovative Health Solutions
  • 6.2.2 Biofertilizers/BioPesticides
  • 6.2.3 Agricultural Biotechnology
  • 6.2.4 Biofuel
• 6.3 Challenges
  • 6.3.1 Consumer Preferences & Market Uncertainty
  • 6.3.2 Cost Pressures
  • 6.3.3 Competition from Developing Countries like India & China
  • 6.3.4 Public Acceptance
• 6.4 Future Outlook, 2010

7. Key Players and Company Profiles

• 7.1 Chiron Corporation
• 7.2 Amgen Inc.
• 7.3 Biogen Idec, Inc.
• 7.4 Applied Biosystems
• 7.5 Genentech
• 7.6 Baxter International Inc.

8. Annexure I: Government Initiatives and Regulations

• 8.1 Food and Drug Administration (FDA)
  • 8.1.1 Food
  • 8.1.2 Regulation of Drugs and Biologic Products
• 8.2 United States Department of Agriculture (USDA)
• 8.3 United States Environmental Protection Agency (USEPA)

List of Figures:

• Figure 3-1: Global - Biotechnology Market (in Billion US$), 2001-2005
• Figure 3-2: Global - Biotechnology Market Share by Region (%), 2005
• Figure 3-3: Global - Biotechnology Market Share by Segment (%), 2005
• Figure 3-4: Global - Forecast for Biotechnology Market (in Billion US$), 2006-2010
• Figure 3-5: US - Biotechnology Market (in Billion US$), 2001-2006E
• Figure 3-6: US - Biotechnology Market Share by Segment (%), 2005
• Figure 3-7: US - Distribution Companies by Segment (%), 2005
• Figure 4-1: US - Net Loss Relative to Revenue (%), 1991-2005
• Figure 4-2: US - Employment in Biomedical Sector (%), 2005
• Figure 4-3: US - Interaction among Players in Biomedical and Healthcare Industries
• Figure 4-4: US - Forecast for Clinical Trial Industry (in Billion US$), 2006-2011
• Figure 4-5: US - Clinical Trials (in Numbers), 2003-2006E
• Figure 4-6: US - Forecast for Clinical Trials (in Number), 2007-2011
• Figure 4-7: US - Biotech Financing (in Billion US$), 2004-2006E
• Figure 6-1: US - Biotech Financing (in Billion US$), 2004 & 2005
• Figure 6-2: US - FDA Approvals (in Numbers), 2000 to Jun' 2006
• Figure 6-3: US - Ethanol Demand (in Billion Gallons), 2006-2008E
• Figure 6-4: US - Forecast for Biotech Market (in Billion US$), 2007-2010

List of Tables:

• Table 3-1: Biotechnology Industry Segments and Applications
• Table 4-1: US - Regulatory History of Biomedical Industry
• Table 4-2: US - Stages for Biomedical Companies
• Table 4-3: US - Overall Impact of Biotechnology Derived Crops on Agriculture (2001 & 2003 to 2005)
• Table 4-4: US - Percentage Adoption of Biotechnology Derived Crops (2003-2005)
• Table 4-5: US - Impact of Biotechnology on Crops (Production & Pesticides Reduction), 2005
• Table 4-6: US - Impact of Agricultural Biotechnology on Crops, 2005
• Table 4-7: US - Impact of Bitechnology Corn on Grain and Ethanol Production (1996-2005)
• Table 4-8: US - Selected Biotech M&As (in Million US$), 2005
• Table 4-9: US - Biotech Alliances (in Million US$), 2005
• Table 4-10: US - Biotech Financing (in Million US$), 2004 & 2005
• Table 5-1: Massachusetts - List of FDA Approved Biotechnology Products
• Table 6-1: US - FDA Approvals by Drug Name, Company & Type
• Table 7-1: Amgen Inc. - Key Financials (in Million US$), 2004 to Sep' 2006
• Table 7-2: Biogen Idec, Inc. - Key Financials (in Million US$), 2004 to Sep' 2006
• Table 7-3: Applied Biosystems - Key Financials (in Billion US$), June' 2006
• Table 7-4: Genentech - Key Financials (in Million US$), 2004 to Sep' 2006
• Table 7-5: Baxter International Inc. - Key Financials (in Million US$), 2005 & Sep' 2006
• Table 8-1: US - Federal Biotechnology Regulatory Framework